Antimitotic Agents: all 5,052 studies that test it

Page 37 of 51. Open to participants first (616), then studies with results posted, then the rest; newest registration first within each.

• Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial CarcinomaTerminatedNCT00933374Phase 2
• Study to Evaluate SID 530 Compared to TaxotereCompletedNCT00931008Phase 3
• A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid CancerCompletedNCT00925743Phase 1
• Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin LymphomaTerminatedNCT00920153Phase 3
• Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian CancerTerminatedNCT00919984Phase 2
• Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast CancerCompletedNCT00919880Phase 2
• Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate CancerCompletedNCT00916123Phase 1
• NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)CompletedNCT00916097Phase 2
• A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00912899Phase 1
• A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast CancerStatus unknownNCT00912639Phase 4
• Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast CancerTerminatedNCT00912444Phase 3
• Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast CancerCompletedNCT00912275Phase 1/2
• TC Avastin. ICORG 08-10, V6CompletedNCT00911716Not applicable
• Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced NeoplasmCompletedNCT00908869Phase 1
• Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy RegimenStatus unknownNCT00908336Phase 2
• Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT00906061Phase 2
• Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT00905983Phase 2
• Phase 2 Study MPC-6827 for Recurrent Glioblastoma MultiformeCompletedNCT00892931Phase 2
• Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid TumorsCompletedNCT00891605Phase 1
• Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT00891072Phase 1
• A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)CompletedNCT00889382Phase 1/2
• Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With CancerCompletedNCT00888108Phase 1
• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade GliomaActive, not recruitingNCT00887146Phase 3
• Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian CancerStatus unknownNCT00886717Phase 1/2
• Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid TumorsCompletedNCT00884676Phase 1
• Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced AdenocarcinomaCompletedNCT00883480Not applicable
• Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic CancerCompletedNCT00882973Phase 1
• Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric CarcinomaStatus unknownNCT00881816Phase 1
• Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid TumorsCompletedNCT00881166Phase 1
• Clinical Study of Liposomal Paclitaxel in Chinese PatientsStatus unknownNCT00881101Phase 1
• Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic TherapyActive, not recruitingNCT00877500Phase 2
• Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian CancerCompletedNCT00877253Phase 1
• Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast CancerCompletedNCT00876486Phase 3
• Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast CancerCompletedNCT00872625Phase 1
• Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot StudyStatus unknownNCT00870714Not applicable
• Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT00870532Phase 1
• Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast CancerCompletedNCT00868634Phase 3
• Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck CancerCompletedNCT00868491Phase 2
• Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung CancerCompletedNCT00866528Phase 1
• Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal CancerStatus unknownNCT00865982Phase 2
• Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad PrognosisCompletedNCT00864318Phase 2
• Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR ActivationCompletedNCT00861627Phase 2
• Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck CancerCompletedNCT00855764Phase 2
• Study of EC0489 for the Treatment of Refractory or Metastatic TumorsCompletedNCT00852189Phase 1
• Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionCompletedNCT00849615Phase 2
• The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic LeukemiaStatus unknownNCT00846703Phase 4
• A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast CancerTerminatedNCT00845910Phase 2
• Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric CancerStatus unknownNCT00845884Phase 1/2
• Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive LymphomasCompletedNCT00842595Phase 2
• Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line TreatmentCompletedNCT00840125Phase 2
• Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerStatus unknownNCT00838656Phase 2
• Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the LiverCompletedNCT00833807Phase 1
• Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-TaxCompletedNCT00826852Phase 2
• Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic MalignanciesCompletedNCT00825487Phase 1
• Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal CavityCompletedNCT00825201Phase 1
• Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical CancerStatus unknownNCT00823186Phase 1
• TaxXel: Taxotere and Xeloda in Esophageal CancerStatus unknownNCT00821912Phase 1/2
• Local Paclitaxel Delivery for SFA DiseaseCompletedNCT00821028Not applicable
• Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung CancerCompletedNCT00819728Phase 2
• Paclitaxel and Cisplatin for Thymic NeoplasmTerminatedNCT00818090Phase 2
• Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)Status unknownNCT00817583Phase 2
• Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's LymphomaStatus unknownNCT00816959Phase 3
• Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal CarcinomaStatus unknownNCT00816855Phase 2
• Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal CarcinomaStatus unknownNCT00816816Phase 2
• Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal AdenocarcinomaCompletedNCT00816543Phase 2
• Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerCompletedNCT00814086Phase 1
• Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT00813332Phase 4
• A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid TumorsTerminatedNCT00811993Phase 1
• Taxotere New Indication - Gastric Cancer Treatment Registration TrialCompletedNCT00811447Phase 3
• Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)WithdrawnNCT00811031Phase 2
• A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate CancerCompletedNCT00808418Phase 1
• Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination ChemotherapyStatus unknownNCT00807261Phase 2
• Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)TerminatedNCT00805012Phase 2
• Lapatinib and Ixabepilone in Treating Patients With Advanced Solid TumorsTerminatedNCT00804310Phase 1
• Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab TherapyCompletedNCT00803556Phase 1
• ERCC1 Targeted TrialTerminatedNCT00801736Phase 3
• Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by SurgeryStatus unknownNCT00801411Phase 2
• Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's DiseaseStatus unknownNCT00797472Phase 2
• Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate CancerStatus unknownNCT00796458Phase 3
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00793897Phase 1
• Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)TerminatedNCT00790894Phase 2
• A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid TumorsCompletedNCT00786669Phase 1
• Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid CancerStatus unknownNCT00786552Phase 2
• Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer PatientsStatus unknownNCT00786110Phase 2
• High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative PatientsCompletedNCT00784537Phase 2/3
• Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)TerminatedNCT00783471Phase 2
• Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTICStatus unknownNCT00779714Phase 3
• Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.Status unknownNCT00777673Phase 2
• PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast CancerWithdrawnNCT00774241Phase 4
• A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast CancerCompletedNCT00773695Phase 2
• A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.CompletedNCT00773188Phase 1
• Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian CancerCompletedNCT00772863Phase 2
• A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian CancerStatus unknownNCT00772798Phase 2
• Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx CarcinomaCompletedNCT00772681Phase 4
• Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)CompletedNCT00771563Phase 3
• Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN StudyCompletedNCT00768859Phase 2
• Phase II Avastin Trial for Stage IIIB/IV NSCLCTerminatedNCT00766246Phase 2
• Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast CancerStatus unknownNCT00764972Phase 1/2
• Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic LeukemiaStatus unknownNCT00764907Phase 3
• Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL PositiveCompletedNCT00763763Phase 2

← Antimitotic Agents overview